Engineered polypeptide conjugates using transglutaminase
US-2024009319-A1 · Jan 11, 2024 · US
Anti-tim3 antibodies and methods of use
US2023279109A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2023279109-A1 |
| Application number | US-202318186783-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 20, 2023 |
| Priority date | Nov 6, 2014 |
| Publication date | Sep 7, 2023 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides anti-TIM3 antibodies and methods of using the same.
First claim
Opening claim text (preview).
1 . An isolated antibody that binds to TIM3, wherein the antibody: induces internalization of TIM3 (in a FACS assay on TIM3 expressing RPMI8226 cells (ATCC ® CCL-155™)) of at least 45% after 120 Minutes at 37° C.
Assignees
Inventors
Classifications
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title
- A61K47/6817Primary
Toxins · CPC title
against the T-cell receptor (TcR)-CD3 complex · CPC title
against molecules with a "CD"-designation, not provided for elsewhere · CPC title
- C07K16/2803Primary
against the immunoglobulin superfamily · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2023279109A1 cover?
- The invention provides anti-TIM3 antibodies and methods of using the same.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification A61K47/6817. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Sep 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).